- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04543331
Estudio observacional para evaluar la resolución de fluidos y la eficacia en pacientes que reciben Beovu en la degeneración macular neovascular relacionada con la edad (BLUE SKY)
ESTUDIO OBSERVACIONAL PARA EVALUAR LA RESOLUCIÓN Y LA EFICACIA DE LOS LÍQUIDOS EN PACIENTES QUE RECIBEN Beovu (Brolucizumab) Bajo esquemas de tratamiento clave en la degeneración macular neovascular relacionada con la edad
This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".
Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.
All patients were documented either in the AMD or DME-module (Full Analysis Set).
For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Aschersleben, Alemania, 06449
- Novartis Investigative Site
-
Bayreuth, Alemania, 95445
- Novartis Investigative Site
-
Berlin, Alemania, 10713
- Novartis Investigative Site
-
Berlin, Alemania, 14163
- Novartis Investigative Site
-
Bonn, Alemania, 53105
- Novartis Investigative Site
-
Breisach, Alemania, 79206
- Novartis Investigative Site
-
Chemnitz, Alemania, 09113
- Novartis Investigative Site
-
Cologne, Alemania, 50968
- Novartis Investigative Site
-
Dresden, Alemania, 01067
- Novartis Investigative Site
-
Dresden, Alemania, 01324
- Novartis Investigative Site
-
Esslingen am Neckar, Alemania, 73728
- Novartis Investigative Site
-
Glauchau, Alemania, 08371
- Novartis Investigative Site
-
Homburg, Alemania, 66421
- Novartis Investigative Site
-
Hösbach, Alemania, 63768
- Novartis Investigative Site
-
Kiel, Alemania, 24103
- Novartis Investigative Site
-
Leipzig, Alemania, 04106
- Novartis Investigative Site
-
Magdeburg, Alemania, 39104
- Novartis Investigative Site
-
Marienberg, Alemania, 09496
- Novartis Investigative Site
-
Münster, Alemania, 48145
- Novartis Investigative Site
-
Neubrandenburg, Alemania, 17036
- Novartis Investigative Site
-
Schönebeck, Alemania, 39218
- Novartis Investigative Site
-
Stralsund, Alemania, 18435
- Novartis Investigative Site
-
Sulzbach, Alemania, 66280
- Novartis Investigative Site
-
Torgau, Alemania, 04860
- Novartis Investigative Site
-
Waren, Alemania, 17192
- Novartis Investigative Site
-
Würzburg, Alemania, 97080
- Novartis Investigative Site
-
-
Bavaria
-
Munich, Bavaria, Alemania, 81377
- Novartis Investigative Site
-
Neuburg A.d. Donau, Bavaria, Alemania, 86633
- Novartis Investigative Site
-
Würzburg, Bavaria, Alemania, 97080
- Novartis Investigative Site
-
Würzburg, Bavaria, Alemania, 97070
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Alemania, 60590
- Novartis Investigative Site
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Alemania, 37075
- Novartis Investigative Site
-
Osnabrück, Lower Saxony, Alemania, 49076
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Alemania, 18057
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Trier, Rhineland-Palatinate, Alemania, 54296
- Novartis Investigative Site
-
-
Saarland
-
Saarbrücken, Saarland, Alemania, 66111
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Alemania, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Alemania, 04103
- Novartis Investigative Site
-
Schneeberg, Saxony, Alemania, 08289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Alemania, 06118
- Novartis Investigative Site
-
-
Thuringia
-
Jena, Thuringia, Alemania, 07740
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.
Descripción
Inclusion Criteria:
The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:
- Diagnosis of nAMD or visual impairment due to DME
- Male and Female nAMD and DME patients with ≥18 years of age at index
- Decision to treat with brolucizumab at baseline visit
- Signed written informed consent
- Patients for whom a therapy with brolucizumab was medically indicated
- Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening
Exclusion Criteria:
- Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
- Patients treated for RVO or CNV other than nAMD
- Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
- Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
- Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
- Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
- Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
- Patients participating in parallel in an interventional clinical trial
- Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
- Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
- Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
- Pregnancy and breast-feeding
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
treatment naïve patients
Patients being the first time treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
|
pre-treated patients
Patients already being treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
Periodo de tiempo: Month 12
|
This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch). |
Month 12
|
|
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
Periodo de tiempo: Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Morphological CNV-Changes under clinic specific routine treatment schemes
Periodo de tiempo: Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Percent of patients maintained on q12w dosing after loading through Week 52
Periodo de tiempo: After loading, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study. |
After loading, month 12
|
|
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
Periodo de tiempo: Baseline, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes. |
Baseline, month 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
Periodo de tiempo: Baseline
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline
|
|
Evaluate anatomical parameters during treatment with brolucizumab
Periodo de tiempo: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
|
Evaluate VA change from baseline during treatment with brolucizumab
Periodo de tiempo: Baseline, month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Baseline, month 24
|
|
Estimate number of anti-VEGF injections, visits and injection intervals
Periodo de tiempo: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate percentage of switchers during first 6 months and characterize switchers
Periodo de tiempo: Baseline, month 6
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 6
|
|
Estimate discontinuation rate and time to discontinuation
Periodo de tiempo: Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess retreatment criteria
Periodo de tiempo: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the number of OCT
Periodo de tiempo: Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess the safety of brolucizumab
Periodo de tiempo: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate anatomical effectiveness
Periodo de tiempo: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate treatment intervals
Periodo de tiempo: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Describe implementation of treatment schemes into clinical practice
Periodo de tiempo: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
Periodo de tiempo: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
Periodo de tiempo: Month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 12
|
|
Evaluate anatomical parameters during treatment with brolucizumab
Periodo de tiempo: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Characterize VA change from baseline during treatment with brolucizumab
Periodo de tiempo: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate discontinuation rate during first year of brolucizumab treatment
Periodo de tiempo: Baseline, month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 12
|
|
Estimate time to discontinuation (persistence)
Periodo de tiempo: Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the treatment burden
Periodo de tiempo: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate the number of OCT and the number of visits with/without OCT
Periodo de tiempo: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Month 1-12 and 13-24
|
|
Assess safety of brolucizumab
Periodo de tiempo: Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CRTH258ADE02
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .